ENCell

ENCell Co., Ltd. is a South Korean biotechnology company specialising in the development and manufacturing of advanced cell and gene therapies.

Company Description

Established in April 2018 as a spin-off from Samsung Medical Center, ENCell Co., Ltd. has rapidly positioned itself as a leader in the biotechnology sector. The company's mission is to make a positive difference in the world through the development of innovative pharmaceutical products, aiming to improve patients' quality of life and combat various diseases. Recognised for its cutting-edge technology and expertise, ENCell has been listed on the KOSDAQ, reflecting its commitment to excellence and transparency.

Key Products and Services

• Contract Development and Manufacturing (CDMO) Services: ENCell offers comprehensive CDMO services for cell and gene therapies, operating globally recognised GMP facilities. Their ROCKET Platform provides multi-product GMP production technology, enhancing quality management and enabling the company to secure contracts for global products.

• Contract Quality Testing (CQT) Services: The company conducts thorough quality and characterisation testing for all samples generated during the production process, including raw materials, in-process controls, drug substances, drug products, and stability testing, ensuring the highest quality standards are met.

• Therapeutic Development: ENCell is actively developing next-generation stem cell therapies targeting rare diseases such as Charcot-Marie-Tooth disease and Duchenne muscular dystrophy. Their platform technology addresses key challenges in cell ageing, efficacy, and high-yield production, offering cost-effective solutions to enhance productivity and profitability.

ENCell Co., Ltd. remains steadfast in its commitment to advancing healthcare through innovative solutions in cell and gene therapy. By upholding the highest quality standards and fostering close collaborations with clients, ENCell continues to contribute significantly to the biotechnology industry, aiming to improve patient outcomes and address unmet medical needs globally.